

SPIRIT 2 CML TRIAL	EudraCT NUMBER: 2007-006185-15
Site number:	Site name:
Principal Investigator name:	Principal Investigator signature:

Source data and documents

GCP defines **source data** as: All information in original records and certified copies of original records of clinical findings, observations, or other activities in a clinical trial necessary for the reconstruction and evaluation of the trial. Source data are contained in source documents (original records or certified copies).

Source documents are: Original documents, data, and records relevant to the clinical trial. For SPIRIT 2 these may include hospital notes (including clinic notes, clinical letters, quality of life questionnaires, laboratory results etc).

Source data must adhere to ALCOA standards:

Attributable: is it obvious who wrote it (signed/initialled)?

Legible: can it be read?

Contemporaneous: been recorded in a timely fashion (and dated)?

Original: or if it is a copy has it been verified as an exact (accurate and complete) copy of the original?

Accurate: is this a correct reflection of events?

By signing the consent form the patient is confirming that responsible individuals from the trial team may have access to their records. SPIRIT 2 monitors will require direct access to source data and documents for verification of trial procedures and/or trial data.

Please indicate below where the source data for the SPIRIT 2 data will be recorded:

Item	Location of source data
<i>e.g. Adverse events:</i>	<i>Medical notes including patient history pages and medical letters (correspondence section).</i>
<i>e.g. Bone marrow reports: cytogenetics</i>	<i>A verified copy of the electronic report will be filed in the patient's CRF.</i>
Medical history:	
Physical examinations: liver, spleen, lymphadenopathy.	
Physical examination: ECOG score	
Bone marrow reports: cytogenetics	
Bone marrow reports: morphology	
Adverse events	
Concurrent medications	
Laboratory results:	